Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17278409 | 0.83 | PARP1 (0.39) | PARP1TNKSTNKS2CYP11B1CYP11B2 | |
| SCHEMBL15840579 | 0.79 | TNF (0.36) | TNF | |
| SCHEMBL15840573 | 0.78 | ALOX5AP (0.31) | — | |
| SCHEMBL15819804 | 0.77 | TNF (0.34) | TNF | |
| SCHEMBL15840577 | 0.74 | NCF1 (0.43) | ACHEKCNH2HSP90AB1 | |
| SCHEMBL15840575 | 0.74 | CNR2 (0.34) | TNF | |
| SCHEMBL17301337 | 0.72 | PDPK1 (0.33) | TNF | |
| SCHEMBL10669681 | 0.70 | CES2 (0.40) | PARP1TNKSTNKS2CYP11B1CYP11B2 | |
| SCHEMBL15840581 | 0.70 | NR4A2 (0.34) | — | |
| SCHEMBL22304446 | 0.69 | ACHE (0.46) | PARP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192372-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | ALDEYRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230149383-A1 | QUINOLINE COMPOUNDS FOR TREATING LUNG, LIVER, AND KIDNEY DISEASES, DISORDERS, OR CONDITIONS | ALDEYRA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-9687481-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9687481-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9604997-B2 | Peri-carbinols | ALDEYRA THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604997-B2 | Peri-carbinols | ALDEYRA THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150344432-A1 | PERI-CARBINOLS | Ricerca Biosciences, LLC | 2015-12-03 | — | — | US | disclosed |
| US-20150344432-A1 | PERI-CARBINOLS | Ricerca Biosciences, LLC | 2015-12-03 | — | — | US | disclosed |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-11-26 | — | — | US | disclosed |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-11-26 | — | — | US | disclosed |
| WO-2014116836-A2 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014100425-A1 | PERI-CARBINOLS | ALDEXA THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344432-A1 | PERI-CARBINOLS | PLIN1, PLIN3, PLIN5 | PARP1 365/4885TNKS 3135/4885TNKS2 2929/4885 |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | PARP1 3007/4885TNKS 2926/4885TNKS2 2602/4885 |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | PARP1 301/4885TNKS 2762/4885TNKS2 3140/4885 |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | PARP1 301/4885TNKS 2762/4885TNKS2 3140/4885 |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | PARP1 3007/4885TNKS 2926/4885TNKS2 2602/4885 |
| US-20230149383-A1 | QUINOLINE COMPOUNDS FOR TREATING LUNG, LIVER, AND KIDNEY DISEASES, DISORDERS, OR CONDITIONS | GLS, PYGL, REN | PARP1 3708/4885TNKS 4795/4885TNKS2 4747/4885 |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | PARP1 301/4885TNKS 2762/4885TNKS2 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.